
Arrange your collection
Choose your location, add the test to your care bag and select a time. If you are booking for someone else, assign the test to them in checkout.
Choose collection locationTumour Markers · Individual laboratory test
CA 15-3 is a marker that may be followed in selected patients with an established breast cancer diagnosis. A trend can be more informative than a single figure.
Clinical authorDr Nirupama SabhapathySpecialist Clinical Pathology
Understanding the test
Also called Breast Cancer Marker
An oncology team may use serial CA 15-3 in selected patients to add context to other evidence of treatment response.
CA 15-3 may be used alongside other findings to monitor some patients with established breast cancer.
Repeat results are more meaningful when interpreted with symptoms, examination and imaging.
Before your sample
No fasting is required. Record the treatment stage and use the same laboratory or bring prior assay details when following changes over time.
A clinician takes a small sample of blood from a vein. The laboratory uses serum, the liquid separated from the blood after it clots.
Smart Report
24 hoursLaboratory turnaround
An isolated increase does not prove progression. Your treating team compares the trend with symptoms, examination and imaging before deciding on its significance.
From sample to follow-up

Choose your location, add the test to your care bag and select a time. If you are booking for someone else, assign the test to them in checkout.
Choose collection locationLook for CA-15-3 in your report. Use the sample type and collection time when comparing it with an earlier report.
Explore Smart Report
Compare the trend with your oncology team's clinical assessment and imaging before drawing conclusions about treatment response.
Health packages
Compare the other tests in each package before choosing.
Patient questions
No. A normal marker does not exclude breast cancer and an increase does not establish progression. Your cancer team interprets the trend alongside your assessment.
Not on its own. Higher values are seen more often in metastatic or advanced breast cancer, particularly when it involves bone or liver, but chronic liver disease, benign breast conditions and other cancers can also raise it. Whether cancer has spread is decided by imaging and examination, with the marker trend as supporting information.
It is helpful but not conclusive. Many breast cancers, especially early ones, never raise CA-15-3, so in those cases a normal value says little about how the disease is behaving. The marker is most informative when your own trend is followed over time, and your oncologist always weighs it against examination, imaging and how you feel.
KEEP EXPLORING
Open a package to see exactly which tests it includes.

A defined selection of tumour markers, with a blood count and stool occult blood, for clinician-directed assessment. These results cannot confirm or rule out cancer on their own.

Blood count, liver, kidney, cholesterol, blood sugar and urine tests: the essentials in one visit.

A complete blood count with liver enzymes, cholesterol, kidney markers and fasting blood sugar from one blood sample.

A broad whole-body screen covering blood, urine and stool with kidney, liver, lipid, iron, diabetes and vitamin markers.
Choosing for a particular need?
We can help you read the options.
Your next step
Written by Dr Nirupama Sabhapathy, Specialist Clinical Pathology. Medically reviewed by Dr Joyce Jose, Specialist Clinical Pathology, on .
Catalogue information and AED price checked on 2 November 2026. Clinical suitability, preparation, collection arrangements and turnaround are confirmed for your selected test.